Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of R-406. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK known ✓ | P43405 | 14/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | TYRO3 | Q06418 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | STK16 | O75716 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 2/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 2/20 | 1.00 |
| ▸ | MST1R | Q04912 | 2/20 | 1.00 |
| ▸ | TNK1 | Q13470 | 2/20 | 1.00 |
| ▸ | IKBKE | Q14164 | 2/20 | 1.00 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 1.00 |
| ▸ | ADCK1 | Q86TW2 | 2/20 | 1.00 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 1.00 |
| ▸ | NEK9 | Q8TD19 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | IRAK3 | Q9Y616 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| R-406 SCHEMBL29358236 | 1.00 | SYK (1.00) | SYKPTK2AURKAADORA3TYRO3 | |
| R-406 SCHEMBL12903997 | 0.96 | SYK (0.92) | SYKPTK2AURKAADORA3TYRO3 | |
| R-406 SCHEMBL12903982 | 0.95 | SYK (0.91) | SYKPTK2AURKAADORA3TYRO3 | |
| SCHEMBL2627469 | 0.95 | SYK (0.91) | SYKPTK2AURKAADORA3TYRO3 | |
| SCHEMBL1383686 | 0.94 | SYK (0.89) | SYKPTK2AURKAADORA3TYRO3 | |
| R-406 SCHEMBL12904000 | 0.94 | SYK (0.89) | SYKPTK2AURKAADORA3TYRO3 | |
| SCHEMBL11937326 | 0.93 | SYK (0.87) | SYKPTK2AURKAADORA3TYRO3 | |
| R-406 SCHEMBL12903973 | 0.93 | SYK (0.86) | SYKPTK2AURKAADORA3TYRO3 | |
| R-406 SCHEMBL12904025 | 0.92 | SYK (0.84) | SYKPTK2AURKAADORA3TYRO3 | |
| R-406 SCHEMBL1222514 | 0.91 | ADORA3 (1.00) | SYKPTK2AURKAADORA3TYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 794 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | claimed |
| EP-4430047-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | claimed |
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. | 2024-09-12 | — | — | US | claimed |
| CN-118475580-A | Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof | 普罗根托斯治疗公司 | 2024-08-09 | — | — | CN | claimed |
| US-20240122927-A1 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | PURDUE RESEARCH FOUNDATION | 2024-04-18 | — | — | US | claimed |
| EP-4351552-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| CN-117794543-A | Combination therapy with SETD2 inhibitors | EPIZYME股份有限公司 | 2024-03-29 | — | — | CN | claimed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | claimed |
| US-20230287510-A1 | COMPOSITIONS, PANELS, AND METHODS FOR CHARACTERIZING CHRONIC LYMPHOCYTIC LEUKEMIA | THE BROAD INSTITUTE, INC. (US) | 2023-09-14 | — | — | US | claimed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | claimed |
| CN-111346101-B | Application of TAMATINIB in preparation of medicine for treating glioma | 中山大学 | 2023-01-24 | — | — | CN | claimed |
| WO-2022261243-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2022-12-15 | — | — | WO | claimed |
| CN-111346096-B | Pharmaceutical composition for preventing or treating glioma | 中山大学 | 2022-11-22 | — | — | CN | claimed |
| CN-114585356-A | Methods of preventing or treating diseases associated with VEGFR and/or VEGF inhibition | 上海岸阔医药科技有限公司 | 2022-06-03 | — | — | CN | claimed |
| WO-2022035723-A1 | COMPOSITIONS, PANELS, AND METHODS FOR CHARACTERIZING CHRONIC LYMPHOCYTIC LEUKEMIA | THE BROAD INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | claimed |
| US-20220000880-A1 | METHOD AND COMPOSITION EMBODIMENTS FOR TREATING ACUTE MYELOID LEUKEMIA | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-06 | — | — | US | claimed |
| EP-3191098-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 Therapeutics, Inc. (US) | 2017-07-19 | — | — | EP | claimed |
| WO-2016040858-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| US-20090012045-A1 | Methods of Treating Cell Proliferative Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | claimed |
| EP-3325513-B1 | ANTI-PD-L1 ANTIBODIES AND USES THEREOF | I MAB BIOPHARMA CO LTD (CN) | 2026-05-20 | — | — | EP | disclosed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260125683-A1 | TREATMENT OF CANCERS HAVING A DRUG-RESISTANT MESENCHYMAL CELL STATE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3870566-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260116987-A1 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2026089992-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4725558-A2 | IMMUNOABLATIVE THERAPIES | AVM Biotechnology, LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12599592-B2 | Therapeutic small molecules for treatment of pulmonary hypertension | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260098098-A1 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4234030-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260090966-A1 | UROLITHIN COMPOSITIONS | AMAZENTIS SA (CH) | 2026-04-02 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12582612-B2 | Pharmaceutical composition of Siglec-binding agents | CYTODIGM, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3860612-B1 | IMMUNOABLATIVE THERAPIES | AVM BIOTECHNOLOGY LLC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12565502-B2 | Substituted 1′,2′-dihydro-3′h-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c] [1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | PHARMACOSMOS HOLDING A/S (KR) | 2026-03-03 | — | — | US | disclosed |
| EP-4695260-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-3641762-B1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4681715-A2 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12527798-B2 | Preservation of immune response during chemotherapy regimens | PHARMACOSMOS HOLDING A/S (DK) | 2026-01-20 | — | — | US | disclosed |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-12522570-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4667499-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | Gilead Sciences, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4667056-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12497404-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | PHARMACOSMOS HOLDING A/S (DK) | 2025-12-16 | — | — | US | disclosed |
| US-20250376484-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250376474-A1 | RET-LDD PROTEIN DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4076450-B1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| WO-2025245003-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4371987-B9 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4652997-A2 | CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | Pharmacosmos Holding A/s (DK) | 2025-11-26 | — | — | EP | disclosed |
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12479855-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | PHARMACOSMOS HOLDING A/S (DK) | 2025-11-25 | — | — | US | disclosed |
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12448400-B2 | KRAS G12D modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12441740-B2 | N/O-linked degrons and degronimers for protein degradation | C4 THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250304592-A1 | MORPHIC FORMS OF G1T38 AND METHODS OF MANUFACTURE THEREOF | PHARMACOSMOS HOLDING A/S (DK) | 2025-10-02 | — | — | US | disclosed |
| US-12421220-B2 | Bicyclic-substituted glutarimide cereblon binders | C4 THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250289827-A1 | MORPHIC FORMS OF A MUTANT BRAF DEGRADER AND METHODS OF MANUFACTURE THEREOF | C4 THERAPEUTICS, INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250288572-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY VASCULAR DISEASE | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2025-09-18 | — | — | US | disclosed |
| EP-4371987-B1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4153597-B1 | CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | PHARMACOSMOS HOLDING AS (DK) | 2025-09-10 | — | — | EP | disclosed |
| EP-4232463-B1 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250270226-A1 | SUBSTITUTED 1',2'-DIHYDRO-3'H-SPIRO[CYCLOHEXANE-1,4'-PYRIMIDO[5',4':4,5]PYRROLO[2,1-c][1,2,4]TRIAZIN]-3'-ONES AS CYCLIN-DEPENDENT KINASE INHIBITORS | PHARMACOSMOS HOLDING A/S (DK) | 2025-08-28 | — | — | US | disclosed |
| US-20250270174-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2025-08-28 | — | — | US | disclosed |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4600247-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-12377100-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250243213-A1 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | PHARMACOSMOS HOLDING A/S (DK) | 2025-07-31 | — | — | US | disclosed |
| US-20250243214-A1 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | PHARMACOSMOS HOLDING A/S (DK) | 2025-07-31 | — | — | US | disclosed |
| US-12371442-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12364697-B2 | G1T38 superior dosage regimes | PHARMACOSMOS HOLDING A/S (DK) | 2025-07-22 | — | — | US | disclosed |
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. | 2025-07-17 | — | — | US | disclosed |
| US-12358887-B2 | IKAROS Zinc Finger Family degraders and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| WO-2025137640-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12338233-B2 | PD-1/Pd-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250199015-A1 | CYCLIN-DEPENDENT KINASE 2 INHIBITORS FOR MEDICAL TREATMENT | INCYCLIX BIO, LLC (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250197421-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-3781556-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-06-18 | — | — | EP | disclosed |
| US-12318403-B2 | 2′3′-cyclic dinucleotides and prodrugs thereof | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2025-06-03 | — | — | US | disclosed |
| US-12312360-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | PHARMACOSMOS HOLDING A/S (DK) | 2025-05-27 | — | — | US | disclosed |
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250154172-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-05-15 | — | — | US | disclosed |
| WO-2025096589-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4547657-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-114245807-B | FLT3L-FC fusion proteins and methods of use | 吉利德科学公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250136621-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-05-01 | — | — | US | disclosed |
| US-12285431-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | PHARMACOSMOS HOLDING A/S (DK) | 2025-04-29 | — | — | US | disclosed |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250127903-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250122179-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250115580-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12269812-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250109147-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-04-03 | — | — | US | disclosed |
| EP-4529477-A1 | POROUS EXPANDING BIOCOMPATIBLE SCAFFOLDS | Danmarks Tekniske Universitet (DK) | 2025-04-02 | — | — | EP | disclosed |
| EP-3386968-B1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDS | UNIV ILLINOIS (US) | 2025-04-02 | — | — | EP | disclosed |
| EP-4529468-A1 | FORMULATION OF API'S AND EXCIPIENT'S IN AN ICELL VIA HYDROPHOBIC ION PAIRING | Danmarks Tekniske Universitet (DK) | 2025-04-02 | — | — | EP | disclosed |
| US-20250101030-A1 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | PHARMACOSMOS HOLDING A/S (DK) | 2025-03-27 | — | — | US | disclosed |
| US-20250101037-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-20250100998-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | disclosed |
| US-20250101042-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | disclosed |
| EP-4525922-A1 | METHOD FOR TREATING AUTOIMMUNE DISEASE | Suntec Medical, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-12258346-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| CN-119654168-A | Methods for treating autoimmune diseases | 欣扬生医股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2025052354-A1 | SYK INHIBITORS FOR USE IN THE TREATMENT OF IMMUNE CHECKPOINT INHIBITION INDUCED ADVERSE EVENTS | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025054530-A1 | PYRIMIDINE-CONTAINING POLYCYCLIC DERIVATIVES AS KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025054347-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4520333-A1 | SYK INHIBITORS FOR USE IN THE TREATMENT OF IMMUNE CHECKPOINT INHIBITION INDUCED ADVERSE EVENTS | Albert-Ludwigs-Universität Freiburg (DE) | 2025-03-12 | — | — | EP | disclosed |
| US-20250064969-A1 | METHOD FOR TREATING AUTOIMMUNE DISEASE | SUNTEC MEDICAL INC (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250066328-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-27 | — | — | US | disclosed |
| EP-4511127-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-113767098-B | Solid forms of Toll-like receptor modulators | 吉利德科学公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-113906023-B | Solid forms of TOLL-like receptor modulators | 吉利德科学公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20250057957-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-20250059208-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-20 | — | — | US | disclosed |
| CN-119487038-A | KRAS G12D modulating compounds | 吉利德科学公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119431579-A | Anti-CD 73 antibodies and methods of use thereof | 艾吉纳斯公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-4504256-A1 | COMBINATIONS OF ANTIBODY THERAPIES FOR TREATING COLORECTAL CANCER | GILEAD SCIENCES, INC. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20250043014-A1 | ANTIBODY MOLECULES TO APRIL AND USES THEREOF | Visterra, Inc. (US) | 2025-02-06 | — | — | US | disclosed |
| US-20250042922-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| EP-4499146-A1 | COMBINATION THERAPY FOR TREATING TROP-2 EXPRESSING CANCERS | GILEAD SCIENCES, INC. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-12213977-B2 | Methods and compositions for treating melanoma | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-04 | — | — | US | disclosed |
| WO-2025024663-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20250034282-A1 | ARRDC1-Mediated Microvesicles (ARMMS) Degrading System and Uses Thereof | Vesigen, Inc. | 2025-01-30 | — | — | US | disclosed |
| WO-2025024811-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| CN-119384415-A | CD73 compounds | 吉利德科学公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20250025461-A1 | TREATMENT OF SEVERE AND UNCOMPLICATED MALARIA | NUREX S.R.L. (IT) | 2025-01-23 | — | — | US | disclosed |
| EP-4493554-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12202842-B2 | MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| CN-119300822-A | Spleen tyrosine kinase inhibitors, compositions, and methods of use | 普渡研究基金会 | 2025-01-10 | — | — | CN | disclosed |
| US-20250011419-A1 | ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREOF | LANOVA MEDICINES LTD (CN) | 2025-01-09 | — | — | US | disclosed |
| WO-2025006704-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| WO-2025006720-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| EP-4483875-A2 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| US-12180225-B2 | N/O-linked degrons and degronimers for protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240398959-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4469448-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240391912-A1 | MORPHIC FORMS OF CFT7455 AND METHODS OF MANUFACTURE THEREOF | C4 THERAPEUTICS, INC. (US) | 2024-11-28 | — | — | US | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| CN-119031937-A | Combination therapy for the treatment of Trop-2 expressing cancers | 吉利德科学公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-119013041-A | Combination of antibody therapies for the treatment of colorectal cancer | 吉利德科学公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240383922-A1 | KRAS Modulating Compounds | GILEAD SCIENCES, INC. | 2024-11-21 | — | — | US | disclosed |
| EP-4464703-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-118924750-A | Application of pyridinamine compound in drug-resistant non-small cell lung cancer after crizotinib treatment | 正大天晴药业集团股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| EP-4458416-A2 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | Gilead Sciences, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| CN-118878461-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240358653-A1 | NOVEL PARTICLE COMPOSITION COMPRISING SIALIC ACID BINDING LIGAND | CYTODIGM, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-4452414-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4455146-A2 | MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF | G1 Therapeutics, Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4452415-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-118843621-A | IKAROS zinc finger family degradation agent and application thereof | 吉利德科学公司 | 2024-10-25 | — | — | CN | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-12122764-B2 | IKAROS zinc finger family degraders and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| WO-2024215754-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-4445902-A2 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| CN-112074535-B | Anti-CD 73 antibodies and methods of use thereof | 艾吉纳斯公司 | 2024-10-11 | — | — | CN | disclosed |
| EP-4245756-B1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-20240307398-A1 | FORMULATIONS, METHODS, KITS, AND DOSAGE FORMS FOR TREATING ATOPIC DERMATITIS AND FOR IMPROVED STABILITY OF AN ACTIVE PHARMACEUTICAL INGREDIENT | Libertas Bio, Inc. | 2024-09-19 | — | — | US | disclosed |
| WO-2024192141-A1 | TREATMENT OF CANCERS HAVING A DRUG-RESISTANT MESENCHYMAL CELL STATE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-4430047-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-4081305-B1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES INC (JP) | 2024-09-18 | — | — | EP | disclosed |
| EP-3956328-B1 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | GILEAD SCIENCES INC (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. | 2024-09-12 | — | — | US | disclosed |
| EP-3454856-B1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-3454862-B1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-112955435-B | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-09-06 | — | — | CN | disclosed |
| EP-4422756-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4423078-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118591537-A | PARP7 inhibitors | 吉利德科学公司 | 2024-09-03 | — | — | CN | disclosed |
| US-12076405-B2 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. | 2024-09-03 | — | — | US | disclosed |
| US-20240287061-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| US-20240285580-A1 | COMPOSITIONS AND METHODS FOR EXTENDED RELEASE CROMAKALIM THERAPY | QLARIS BIO, INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-12070508-B2 | Microparticles and nanoparticles having sulfate groups on the surface | CYTODIGM, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240279186-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-114867530-B | MCL1 inhibitors | 吉利德科学公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240269235-A1 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2024-08-15 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-118488948-A | IKAROS zinc finger family degradation agent and application thereof | 吉利德科学公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-118488946-A | IKAROS zinc finger family degradation agent and application thereof | 吉利德科学公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-118475580-A | Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof | 普罗根托斯治疗公司 | 2024-08-09 | — | — | CN | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-12054469-B2 | Benzothiophene-based selective estrogen receptor downregulator compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240254118-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-08-01 | — | — | US | disclosed |
| US-20240254091-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2024-08-01 | — | — | US | disclosed |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-12048748-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-12048705-B2 | Immunoablative therapies | AVM BIOTECHNOLOGY, LLC (US) | 2024-07-30 | — | — | US | disclosed |
| US-12048747-B2 | Substituted piperidine Degronimers for Target Protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240245677-A1 | SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | US | disclosed |
| US-12036224-B2 | Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient | Libertas Bio, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| CN-111936487-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-113227089-B | Substituted 6-azabenzimidazole compounds as HPK1 inhibitors | 吉利德科学公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-3645001-B1 | MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF | G1 THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-112312909-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-07-02 | — | — | CN | disclosed |
| US-12018076-B2 | Anti-claudin 18.2 antibodies and uses thereof | Lanova Medicines Limited Company (CN) | 2024-06-25 | — | — | US | disclosed |
| CN-118221646-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-113773387-B | PD-L1 antibodies and uses thereof | 天境生物科技(上海)有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240199581-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240197642-A1 | NOVEL DRUG DELIVERY COMPOSITION AND PROCESS FOR BLOOD-BRAIN BARRIER CROSSING | CYTODIGM INC (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4384162-A1 | COMPOSITIONS AND METHODS FOR EXTENDED RELEASE CROMAKALIM THERAPY | Qlaris Bio, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-118178645-A | Combination therapy for the treatment of myelodysplastic syndrome and acute myeloid leukemia | 四十七公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240180919-A1 | EZH2 INHIBITORS FOR TREATING CANCER | EPIZYME INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-11999733-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-118139858-A | Pyrazin-3 (2H) -one derivatives | 吉利德科学公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118078806-A | Inhibitors of targeted spleen tyrosine kinase and their use against type I allergy | 山东农业大学 | 2024-05-28 | — | — | CN | disclosed |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| CN-118084940-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4371987-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | Gilead Sciences, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-118021814-A | Combination therapy with EHMT2 inhibitors | EPIZYME股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024097989-A1 | RET-LDD PROTEIN DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-05-10 | — | — | WO | disclosed |
| CN-118019537-A | Medical application of SHP2 inhibitor combined with EGFR-TKI in treatment and prevention of tumor diseases | 上海翰森生物医药科技有限公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-2024097980-A1 | RET-LDD PROTEIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240150369-A1 | CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-11976072-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| CN-117964757-A | Antibodies and fusion proteins that bind CCR8 and uses thereof | 吉利德科学公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4359411-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-4359413-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-4359415-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-4359389-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240122927-A1 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | PURDUE RESEARCH FOUNDATION | 2024-04-18 | — | — | US | disclosed |
| US-20240124578-A1 | COMBINATION THERAPIES FOR TREATING MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA | Forty Seven, LLC | 2024-04-18 | — | — | US | disclosed |
| EP-4351520-A1 | NOVEL PARTICLE COMPOSITION COMPRISING SIALIC ACID BINDING LIGAND | CYTODIGM, INC. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-3956329-B9 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | GILEAD SCIENCES INC (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4351552-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4351583-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117866991-A | Chimeric antigen receptor for the treatment of cancer | 诺华股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4349413-A2 | COMBINATION THERAPIES FOR TREATING MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA | Forty Seven, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347044-A2 | EGFR DEGRADERS TO TREAT CANCER METASTASIS TO THE BRAIN OR CNS | C4 Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4346886-A1 | INDUCED PLURIPOTENT STEM CELL-BASED CANCER VACCINES | Khloris Biosciences, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11951109-B2 | EZH2 inhibitors for treating lymphoma | Epizyme, Inc. (US) | 2024-04-09 | — | — | US | disclosed |
| CN-114555123-B | Combination therapy for the treatment of myelodysplastic syndrome and acute myeloid leukemia | 四十七公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117794543-A | Combination therapy with SETD2 inhibitors | EPIZYME股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117795076-A | Methods of treating metabolic disorders with inhibitors of mitogen-activated protein kinase 15 (MAP 3K 15) | 雷杰纳荣制药公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024064668-A1 | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY | GILEAD SCIENCES, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| CN-112399874-B | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-117750946-A | Novel particulate compositions comprising sialic acid binding ligands | 希托迪格姆公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-115087488-A9 | Antibodies and fusion proteins that bind CCR8 and uses thereof | 震动疗法股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20240091351-A1 | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY | GILEAD SCIENCES, INC. | 2024-03-21 | — | — | US | disclosed |
| US-20240092921-A1 | ANTIBODY MOLECULES TO APRIL AND USES THEREOF | VISTERRA INC (US) | 2024-03-21 | — | — | US | disclosed |
| US-11932634-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-11925631-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-11926628-B2 | Diacylglyercol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| CN-117693357-A | Cancer vaccine based on induced pluripotent stem cells | 克洛里斯生物科学有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20240076300-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | US | disclosed |
| US-11919869-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-11911469-B2 | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | Center for Excellence in Molecular Cell Science, Chinese Academy of Scienes (CN) | 2024-02-27 | — | — | US | disclosed |
| WO-2024039883-A2 | COMPOSITIONS AND METHODS TO TREAT MYELOPROLIFERATIVE DISORDERS AND MYELOPROLIFERATIVE NEOPLASMS | TRANSLATIONAL DRUG DEVELOPMENT LLC (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4323406-A1 | CO-INHIBITION OF CD47/SIRP? BINDING AND NEDD8-ACTIVATING ENZYME E1 REGULATORY SUBUNIT FOR THE TREATMENT OF CANCER | GILEAD SCIENCES, INC. (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20240051953-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| US-11897878-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11897862-B2 | IKAROS zinc finger family degraders and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11896648-B2 | Interleukin-2 variant proteins fused to human IgG4 Fc and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| WO-2024030968-A1 | COMPOUNDS FOR MODULATING RET PROTEIN | BRYSTOL-MYERS SQUIBB COMPANY (US) | 2024-02-08 | — | — | WO | disclosed |
| CN-110621316-B | Combination therapy with EHMT2 inhibitors | EPIZYME股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-3632446-B3 | IMMUNOABLATIVE THERAPIES | AVM BIOTECHNOLOGY LLC (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| CN-110225927-B | Chimeric antigen receptor for the treatment of cancer | 诺华股份有限公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-117396478-A | Diacylglycerol kinase modulating compounds | 吉利德科学公司 | 2024-01-12 | — | — | CN | disclosed |
| EP-4045083-B1 | COMBINATION THERAPIES FOR TREATING MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA | FORTY SEVEN INC (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-3956329-B1 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | GILEAD SCIENCES INC (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117377671-A | Diacylglycerol kinase modulating compounds | 吉利德科学公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-110913861-B | Morphological forms of G1T38 and methods of making the same | G1治疗公司 | 2024-01-09 | — | — | CN | disclosed |
| WO-2024006929-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| CN-117337179-A | Treatment regimen for inhibitors of BRG1 and BRM enzymatic activity | 福宏治疗公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-117304130-A | MCL-1 inhibitors | 吉利德科学公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230416397-A1 | ANTI-CD73 ANTIBODIES AND METHODS OF USE THEREOF | AGENUS INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230414590-A1 | THERAPEUTIC SMALL MOLECULES FOR TREATMENT OF PULMONARY HYPERTENSION | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-12-28 | — | — | US | disclosed |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| WO-2023227518-A1 | POROUS EXPANDING BIOCOMPATIBLE SCAFFOLDS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023227517-A1 | FORMULATION OF API'S AND EXCIPIENT'S IN AN ICELL VIA HYDROPHOBIC ION PAIRING | DANMARKS TEKNISKE UNIVERSITET (DK) | 2023-11-30 | — | — | WO | disclosed |
| EP-4282435-A1 | FORMULATIONS OF ACTIVE PHARMACEUTICAL INGREDIENTS AND EXCIPIENTS IN ICELLS VIA HYDROPHOBIC ION PAIRING | Danmarks Tekniske Universitet (DK) | 2023-11-29 | — | — | EP | disclosed |
| EP-4282448-A1 | POROUS EXPANDING BIOCOMPATIBLE SCAFFOLDS | Danmarks Tekniske Universitet (DK) | 2023-11-29 | — | — | EP | disclosed |
| US-11827609-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| CN-117105933-A | Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity | 吉利德科学公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230374036-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373950-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230372338-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | FOUNDATION MEDICINE, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372338-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | FOUNDATION MEDICINE, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2023224883-A1 | METHOD FOR TREATING AUTOIMMUNE DISEASE | SUNTEC MEDICAL, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230365682-A1 | COMBINATION THERAPY FOR TREATING COLORECTAL CANCER | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-20230364092-A1 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| CN-112969505-B | Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity | 吉利德科学公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023215756-A2 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY VASCULAR DISEASE | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230355796-A1 | COMBINATION THERAPY FOR TREATING TROP-2 EXPRESSING CANCERS | GILEAD SCIENCES, INC. | 2023-11-09 | — | — | US | disclosed |
| EP-3380522-B1 | ANTIBODY MOLECULES TO APRIL AND USES THEREOF | VISTERRA INC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230348494-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4013420-B1 | METHOD OF BLOCKING OR AMELIORATING CYTOKINE RELEASE SYNDROME | RIGEL PHARMACEUTICALS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4013420-B1 | METHOD OF BLOCKING OR AMELIORATING CYTOKINE RELEASE SYNDROME | RIGEL PHARMACEUTICALS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2023205719-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230339981-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-11795223-B2 | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia | FORTY SEVEN, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| WO-2023196784-A1 | COMBINATIONS OF ANTIBODY THERAPIES FOR TREATING COLORECTAL CANCER | GILEAD SCIENCES, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-112174960-B | Toll-like receptor modulating 4, 6-diamino-pyrido [3,2-D ] pyrimidine compounds | 吉利德科学公司 | 2023-10-10 | — | — | CN | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312736-A1 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| CN-112041311-B | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2023-10-03 | — | — | CN | disclosed |
| US-11771698-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771698-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| CN-111566120-B | 3' cyclic dinucleotides with phosphonate bonds of activated STING adaptor protein | 捷克共和国有机化学与生物化学研究所 | 2023-09-29 | — | — | CN | disclosed |
| US-20230302001-A1 | PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS | G1 THERAPEUTICS, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2023183817-A1 | COMBINATION THERAPY FOR TREATING TROP-2 EXPRESSING CANCERS | GILEAD SCIENCES, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
| WO-2023178181-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295111-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4245756-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230287510-A1 | COMPOSITIONS, PANELS, AND METHODS FOR CHARACTERIZING CHRONIC LYMPHOCYTIC LEUKEMIA | THE BROAD INSTITUTE, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| CN-111511754-B | 2'3' cyclic dinucleotides with phosphonate bonds of activated STING adaptor protein | 捷克共和国有机化学与生物化学研究所 | 2023-09-12 | — | — | CN | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-116744929-A | Compounds and uses thereof | 福霍恩治疗公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230270746-A1 | FORMULATIONS, METHODS, KITS, AND DOSAGE FORMS FOR TREATING ATOPIC DERMATITIS AND FOR IMPROVED STABILITY OF AN ACTIVE PHARMACEUTICAL INGREDIENT | Libertas Bio, Inc. | 2023-08-31 | — | — | US | disclosed |
| EP-4232463-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4234030-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4227302-A1 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3820572-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11723947-B2 | Anti-senescence compounds and uses thereof | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2023-08-15 | — | — | US | disclosed |
| US-11723947-B2 | Anti-senescence compounds and uses thereof | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2023-08-15 | — | — | US | disclosed |
| CN-116568331-A | Pharmaceutical compositions of SIGLEC-binders | 希托迪格姆公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230242508-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116529258-A | Interleukin-2-Fc fusion proteins and methods of use | 吉利德科学公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116507738-A | Kit for detecting one or more target analytes in a sample and methods of making and using the same | 中尺度技术有限责任公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230220106-A1 | ANTIBODIES TARGETING 5T4 AND USES THEREOF | DRAGONFLY THERAPEUTICS INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| EP-3152210-B1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11692038-B2 | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) | GILEAD SCIENCES, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11692042-B2 | Anti-CD73 antibodies and methods of use thereof | AGENUS INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230203202-A1 | PROTEINS BINDING NKG2D, CD16 AND 5T4 | DRAGONFLY THERAPEUTICS INC (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2023122581-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122615-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230190760-A1 | ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS | C4 THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183189-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183262-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| WO-2023107954-A1 | ANTIBODIES TARGETING 5T4 AND USES THEREOF | DRAGONFLY THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107956-A1 | PROTEINS BINDING NKG2D, CD16 AND 5T4 | DRAGONFLY THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-4192458-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| CN-112118845-B | MCL-1 inhibitors | 吉利德科学公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-3490605-B1 | REPLACEMENT OF CYTOTOXIC PRECONDITIONING BEFORE CELLULAR IMMUNOTHERAPY | AVM BIOTECHNOLOGY LLC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11667652-B2 | MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| CN-116178554-A | Anti-claudin 18.2 antibodies and uses thereof | 礼新医药科技(上海)有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-116178555-A | Anti-claudin 18.2 antibodies and uses thereof | 礼新医药科技(上海)有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20230149406-A1 | G1T38 SUPERIOR DOSAGE REGIMES | G1 THERAPEUTICS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643416-B2 | Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | G1 THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2023077030-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076983-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230128322-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | PURDUE RESEARCH FOUNDATION | 2023-04-27 | — | — | US | disclosed |
| WO-2021163064-A9 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | JOUNCE THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230128322-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | PURDUE RESEARCH FOUNDATION | 2023-04-27 | — | — | US | disclosed |
| US-20230128322-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | PURDUE RESEARCH FOUNDATION | 2023-04-27 | — | — | US | disclosed |
| EP-3752501-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2023-04-19 | — | — | EP | disclosed |
| CN-111788228-B | Anti-claudin 18.2 antibodies and uses thereof | 礼新医药科技(上海)有限公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20230116253-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-04-13 | — | — | US | disclosed |
| CN-110475571-B | Replacement for cellular immunotherapy pre-conditioning for cytotoxicity | AVM生物技术有限责任公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20230095223-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| EP-4153597-A1 | CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | G1 Therapeutics, Inc. (US) | 2023-03-29 | — | — | EP | disclosed |
| US-11613577-B2 | Anti-CD73 antibodies and uses thereof | I-MAB (KY) | 2023-03-28 | — | — | US | disclosed |
| US-20230085372-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-20230077104-A1 | L-SEPIAPTERIN AND METHODS OF USE FOR TREATING DISEASES AND DISORDERS | MUSC Foundation for Research Developement | 2023-03-09 | — | — | US | disclosed |
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230060354-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230056284-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230060004-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230058971-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| US-11583531-B2 | Solid forms of a toll-like receptor modulator | GILEAD SCIENCES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2023018958-A1 | COMPOSITIONS AND METHODS FOR EXTENDED RELEASE CROMAKALIM THERAPY | QLARIS BIO, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20230046340-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11571400-B2 | ACAT1 inhibitors for treating cancer | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-07 | — | — | US | disclosed |
| CN-115667530-A | Non-viral DNA vectors and their use for expressing factor IX therapeutics | 世代生物公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20230025878-A1 | Methods Of Treating A Metabolic Disorder With Mitogen-Activated Protein Kinase Kinase Kinase 15 (MAP3K15) Inhibitors | REGENERON PHARMA (US) | 2023-01-26 | — | — | US | disclosed |
| CN-111346101-B | Application of TAMATINIB in preparation of medicine for treating glioma | 中山大学 | 2023-01-24 | — | — | CN | disclosed |
| CN-111346101-B | Application of TAMATINIB in preparation of medicine for treating glioma | 中山大学 | 2023-01-24 | — | — | CN | disclosed |
| CN-111346101-B | Application of TAMATINIB in preparation of medicine for treating glioma | 中山大学 | 2023-01-24 | — | — | CN | disclosed |
| US-20230018687-A1 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | PURDUE RESEARCH FOUNDATION | 2023-01-19 | — | — | US | disclosed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230013585-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20230018687-A1 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | PURDUE RESEARCH FOUNDATION | 2023-01-19 | — | — | US | disclosed |
| US-11555029-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| EP-4114392-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| WO-2023278677-A1 | METHODS OF TREATING A METABOLIC DISORDER WITH MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 15 (MAP3K15) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022271684-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022271677-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022271650-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022271659-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-4103285-A2 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | Jounce Therapeutics, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| US-11529352-B2 | Preservation of immune response during chemotherapy regimens | G1 THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2022261207-A1 | NOVEL PARTICLE COMPOSITION COMPRISING SIALIC ACID BINDING LIGAND | CYTODIGM, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261243-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-4100003-A1 | IMPROVED METHODS AND COMPOSITIONS FOR CROMAKALIM PRODRUG THERAPY | Qlaris Bio, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220387457-A1 | METHODS AND COMPOSITIONS FOR CROMAKALIM PRODRUG THERAPY | QLARIS BIO, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220387569-A1 | INDUCED PLURIPOTENT STEM CELL-BASED CANCER VACCINES | KHLORIS BIOSCIENCES, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| WO-2022256277-A1 | INDUCED PLURIPOTENT STEM CELL-BASED CANCER VACCINES | KHLORIS BIOSCIENCES, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20220389394-A1 | METHODS OF USING FLT3L-Fc FUSION PROTEINS | GILEAD SCIENCES, INC. | 2022-12-08 | — | — | US | disclosed |
| WO-2022245671-A1 | METHODS OF USING FLT3L-FC FUSION PROTEINS | GILEAD SCIENCES, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| CN-111346096-B | Pharmaceutical composition for preventing or treating glioma | 中山大学 | 2022-11-22 | — | — | CN | disclosed |
| CN-111346096-B | Pharmaceutical composition for preventing or treating glioma | 中山大学 | 2022-11-22 | — | — | CN | disclosed |
| CN-115362003-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2022-11-18 | — | — | CN | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-20220340679-A1 | CO-INHIBITION OF CD47/SIRPalpha BINDING AND NEDD8-ACTIVATING ENZYME E1 REGULATORY SUBUNIT FOR THE TREATMENT OF CANCER | GILEAD SCIENCES, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220340535-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220339285-A1 | DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022221304-A1 | CO-INHIBITION OF CD47/SIRPα BINDING AND NEDD8-ACTIVATING ENZYME E1 REGULATORY SUBUNIT FOR THE TREATMENT OF CANCER | GILEAD SCIENCES, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220324890-A1 | CONTROLLED-DELIVERY CROMAKALIM PRODRUGS | QLARIS BIO, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220313826-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220313827-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220306644-A1 | CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2022-09-29 | — | — | US | disclosed |
| US-20220305115-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-09-29 | — | — | US | disclosed |
| US-11453681-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| EP-4058149-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-09-21 | — | — | EP | disclosed |
| US-11446295-B2 | Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors | G1 THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-11446314-B2 | Immunoablative therapies | AVM BIOTECHNOLOGY, LLC (US) | 2022-09-20 | — | — | US | disclosed |
| US-11446297-B2 | Methods for treating hemolytic diseases and sickle cell disease | PURDUE RESEARCH FOUNDATION (US) | 2022-09-20 | — | — | US | disclosed |
| CN-115087488-A | Antibodies and fusion proteins binding to CCR8 and uses thereof | 震动疗法股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-11447461-B2 | Benzothiophene-based selective estrogen receptor downregulators | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-09-20 | — | — | US | disclosed |
| CN-109923106-B | toll-like receptor modulator compounds | 吉利德科学公司 | 2022-09-13 | — | — | CN | disclosed |
| EP-3386500-B1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS | UNIV ILLINOIS (US) | 2022-09-07 | — | — | EP | disclosed |
| EP-4052040-A1 | ANTI-CD47 AND ANTI-CD20 BASED TREATMENT OF BLOOD CANCER | Forty Seven, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-111757764-B | System, kit and method for loading and delivering small volume doses from a syringe | 爱康生物科学股份有限公司 | 2022-09-06 | — | — | CN | disclosed |
| EP-4050030-A1 | ANTI-CD73 ANTIBODIES AND USES THEREOF | I-Mab Biopharma US Limited (US) | 2022-08-31 | — | — | EP | disclosed |
| EP-4045083-A1 | COMBINATION THERAPIES FOR TREATING MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA | Forty Seven, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | C4 THERAPEUTICS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| CN-114867530-A | MCL1 inhibitors | 吉利德科学公司 | 2022-08-05 | — | — | CN | disclosed |
| US-20220241281-A1 | Imidazopyrimidine Derivatives | GILEAD SCIENCES, INC. | 2022-08-04 | — | — | US | disclosed |
| US-11396509-B2 | Solid forms of a toll-like receptor modulator | GILEAD SCIENCES, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20220226336-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2022-07-21 | — | — | US | disclosed |
| EP-4029868-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-07-20 | — | — | EP | disclosed |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-07-14 | — | — | US | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-11384399-B2 | Methods for subtyping diffuse large B-cell lymphoma (DLBCL) | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220213091-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20220194917-A1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-06-23 | — | — | US | disclosed |
| EP-4013420-A1 | METHOD OF BLOCKING OR AMELIORATING CYTOKINE RELEASE SYNDROME | Rigel Pharmaceuticals, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357779-B2 | G1T38 superior dosage regimes | G1 THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220175959-A1 | MICROPARTICLES AND NANOPARTICLES HAVING SULFATE GROUPS ON THE SURFACE | CYTODIGM, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220175789-A1 | EZH2 INHIBITORS FOR TREATING LYMPHOMA | Epizyme, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20220175689-A1 | NOVEL DRUG DELIVERY COMPOSITION AND PROCESS FOR BLOOD-BRAIN BARRIER CROSSING | CYTODIGM, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220175690-A1 | NOVEL DRUG DELIVERY COMPOSITION AND PROCESS FOR BLOOD-BRAIN BARRIER CROSSING | CYTODIGM, INC. | 2022-06-09 | — | — | US | disclosed |
| CN-114599392-A | anti-CD 47 and anti-CD 20 based treatment of leukemia | 四十七公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114585356-A | Methods of preventing or treating diseases associated with VEGFR and/or VEGF inhibition | 上海岸阔医药科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2022108934-A1 | NOVEL DRUG DELIVERY COMPOSITION AND PROCESS FOR BLOOD-BRAIN BARRIER CROSSING | PHOSPHOREX, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022108937-A2 | NOVEL DRUG DELIVERY COMPOSITION AND PROCESS FOR BLOOD-BRAIN BARRIER CROSSING | PHOSPHOREX, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| CN-114555123-A | Combination therapy for the treatment of myelodysplastic syndrome and acute myeloid leukemia | 四十七公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220160746-A1 | 3'3'-CYCLIC DINUCLEOTIDE ANALOGUE COMPRISING A CYCLOPENTANYL MODIFIED NUCLEOTIDE AS STING MODULATOR | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I (CZ) | 2022-05-26 | — | — | US | disclosed |
| US-20220160729-A1 | Replacement of Cytotoxic Preconditioning Before Cellular Immunotherapy | AVM BIOTECHNOLOGY, LLC (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220152078-A1 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2022-05-19 | — | — | US | disclosed |
| US-20220152065-A1 | METHOD OF BLOCKING OR AMELIORATING CYTOKINE RELEASE SYNDROME | RIGEL PHARMACEUTICALS, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220152065-A1 | METHOD OF BLOCKING OR AMELIORATING CYTOKINE RELEASE SYNDROME | RIGEL PHARMACEUTICALS, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| WO-2022103706-A1 | THERAPEUTIC SMALL MOLECULES FOR TREATMENT OF PULMONARY HYPERTENSION | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-19 | — | — | WO | disclosed |
| US-11331276-B2 | Aggregating microparticles for medical therapy | Graybug Vision, Inc. (CA) | 2022-05-17 | — | — | US | disclosed |
| US-20220143061-A1 | 3'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2022-05-12 | — | — | US | disclosed |
| US-20220142935-A1 | PHARMACEUTICAL COMPOSITION OF SIGLEC-BINDING AGENTS | CYTODIGM, INC. | 2022-05-12 | — | — | US | disclosed |
| EP-3990476-A1 | FLT3L-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022087149-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220125884-A1 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220119531-A1 | ANTI-PD-L1 ANTIBODIES AND USES THEREOF | I-MAB (KY) | 2022-04-21 | — | — | US | disclosed |
| EP-3982922-A1 | DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE | Technical University of Denmark (DK) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022076435-A1 | PHARMACEUTICAL COMPOSITION OF SIGLEC-BINDING AGENTS | PHOSPHOREX, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220105098-A1 | EZH2 INHIBITORS FOR TREATING CANCER | Epizyme, Inc. | 2022-04-07 | — | — | US | disclosed |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | disclosed |
| EP-3975997-A1 | MICROPARTICLES AND NANOPARTICLES HAVING SULFATE GROUPS ON THE SURFACE | Phosphorex, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11292812-B2 | 3′3′-cyclic dinucleotides | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2022-04-05 | — | — | US | disclosed |
| US-20220098194-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| EP-3972695-A1 | SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11285218-B2 | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| CN-114245807-A | FLT3L-FC fusion proteins and methods of use | 吉利德科学公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20220073473-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-03-10 | — | — | US | disclosed |
| US-11261193-B2 | Morphic forms of G1T38 and methods of manufacture thereof | GI Therapeutics, Inc. (US) | 2022-03-01 | — | — | US | disclosed |
| US-20220056037-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-02-24 | — | — | US | disclosed |
| EP-3383916-B1 | ANTI-CD73 ANTIBODIES AND USES THEREOF | I MAB BIOPHARMA US LTD (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-114072130-A | Microparticles and nanoparticles having sulfate groups on the surface | 法斯瑞斯公司 | 2022-02-18 | — | — | CN | disclosed |
| WO-2022035723-A1 | COMPOSITIONS, PANELS, AND METHODS FOR CHARACTERIZING CHRONIC LYMPHOCYTIC LEUKEMIA | THE BROAD INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20220049021-A1 | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| EP-3953332-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-11236085-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-RE48898-E1 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20220000880-A1 | METHOD AND COMPOSITION EMBODIMENTS FOR TREATING ACUTE MYELOID LEUKEMIA | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220000880-A1 | METHOD AND COMPOSITION EMBODIMENTS FOR TREATING ACUTE MYELOID LEUKEMIA | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220000880-A1 | METHOD AND COMPOSITION EMBODIMENTS FOR TREATING ACUTE MYELOID LEUKEMIA | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-06 | — | — | US | disclosed |
| WO-2021236650-A1 | CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| EP-3902805-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV Therapeutics Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| US-11160870-B2 | Extended release microparticles and suspensions thereof for medical therapy | Graybug Vision, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
| WO-2021183790-A1 | METHOD FOR TREATMENT OF COVID-19-ASSOCIATED CONDITIONS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-09-16 | — | — | WO | disclosed |
| US-20210283152-A1 | METHOD FOR TREATMENT OF COVID-19-ASSOCIATED CONDITIONS | MIDCAP FINANCIAL TRUST | 2021-09-16 | — | — | US | disclosed |
| US-20210283134-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | FOUNDATION MEDICINE, INC. (US) | 2021-09-16 | — | — | US | disclosed |
| WO-2021178920-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2021-09-10 | — | — | WO | disclosed |
| US-20210275456-A1 | AGGREGATED MICROPARTICLES | Graybug Vision, Inc. (US) | 2021-09-09 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-11090306-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | G1 THERAPEUTICS, INC. | 2021-08-17 | — | — | US | disclosed |
| WO-2021158992-A1 | IMPROVED METHODS AND COMPOSITIONS FOR CROMAKALIM PRODRUG THERAPY | QLARIS BIO, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-3858835-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-11072595-B2 | Benzothiophene-based selective estrogen receptor downregulator compounds | The Board of Trustees of lhe University of Illinois (US) | 2021-07-27 | — | — | US | disclosed |
| WO-2021127561-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3836916-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS | G1 Therapeutics, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| WO-2021119503-A1 | CONTROLLED-DELIVERY CROMAKALIM PRODRUGS | QLARIS BIO, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| US-20210171554-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10980804-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210085607-A1 | CONTINUOUS MICROPARTICLE MANUFACTURE | Graybug Vision, Inc. (US) | 2021-03-25 | — | — | US | disclosed |
| US-20210047286-A1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-02-18 | — | — | US | disclosed |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| WO-2021030526-A1 | METHOD OF BLOCKING OR AMELIORATING CYTOKINE RELEASE SYNDROME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030526-A1 | METHOD OF BLOCKING OR AMELIORATING CYTOKINE RELEASE SYNDROME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| EP-3773576-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20200405721-A1 | G1T38 SUPERIOR DOSAGE REGIMES | G1 THERAPEUTICS, INC. (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200377518-A1 | METHOD OF PREVENTING AND TREATING THROMBOSIS | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-03 | — | — | US | disclosed |
| US-20200377518-A1 | METHOD OF PREVENTING AND TREATING THROMBOSIS | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-03 | — | — | US | disclosed |
| WO-2020243612-A1 | METHOD OF PREVENTING AND TREATING THROMBOSIS | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3738084-A1 | G1T38 SUPERIOR DOSAGE REGIMES | G1 Therapeutics, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200345737-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | PURDUE RESEARCH FOUNDATION | 2020-11-05 | — | — | US | disclosed |
| US-20200338088-A1 | Methods for Treating Neutrophilic Dermatoses with SYK Inhibitors | RUSH UNIVERSITY MEDICAL CENTER (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-10807964-B2 | Benzothiophene-based selective estrogen receptor downregulators | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-10-20 | — | — | US | disclosed |
| WO-2020210630-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020206034-A1 | CELL CYCLE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020206035-A1 | TREATMENT OF CDK4/6 INHIBITOR RESISTANT NEOPLASTIC DISORDERS | G1 THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| EP-3710002-A2 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200283406-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | G1 THERAPEUTICS, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200270271-A1 | PRODRUGS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200216454-A1 | BIFUNCTIONAL MOLECULES FOR HER3 DEGRADATION AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2020-07-09 | — | — | US | disclosed |
| US-20200216406-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | G1 THERAPEUTICS, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-10703747-B2 | Benzothiophene-based selective mixed estrogen receptor downregulators | The Board of Directors of the University of Illinois (US) | 2020-07-07 | — | — | US | disclosed |
| WO-2020140052-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020140054-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| US-10654831-B2 | Antiproliferative pyrimidine-based compounds | G1 THERAPEUTICS, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| WO-2020092845-A1 | METHOD AND COMPOSITION EMBODIMENTS FOR TREATING ACUTE MYELOID LEUKEMIA | RIGEL PHARMACEUTICALS, INC. (US) | 2020-05-07 | — | — | WO | disclosed |
| US-10633362-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20200123126-A1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-04-23 | — | — | US | disclosed |
| US-20200123168-A1 | MORPHIC FORMS OF G1T38 AND METHODS OF MANUFACTURE THEREOF | G1 THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | US | disclosed |
| US-10618905-B2 | Pyrimidine-based compounds for the treatment of cancer | G1 THERAPEUTICS, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20200079752-A1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-03-12 | — | — | US | disclosed |
| US-10577381-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| WO-2020037251-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS TO TREAT MEDICAL DISORDERS | G1 THERAPEUTICS, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| EP-3600440-A1 | REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS | Sienna Biopharmaceuticals, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2020023389-A1 | REDUCED EXPOSURE COMPOSITIONS MODULATING THERAPEUTIC TARGETS | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20190321370-A1 | PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS | G1 THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | US | disclosed |
| US-10441548-B2 | Aggregating microparticles for medical therapy | Graybug Vision, Inc. (US) | 2019-10-15 | — | — | US | disclosed |
| WO-2019191112-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20190292197-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190275040-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE | UNIV YALE (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190275040-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE | UNIV YALE (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190248780-A1 | BENZOTHIOPHENE-BASED SELECTIVE MIXED ESTROGEN RECEPTOR DOWNREGULATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLNOIS (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190247509-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10377735-B2 | Benzothiophene-based selective estrogen receptor downregulators | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-08-13 | — | — | US | disclosed |
| US-10357505-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-07-23 | — | — | US | disclosed |
| WO-2019136204-A1 | METHODS FOR TREATING NEUTROPHILIC DERMATOSES WITH SYK INHIBITORS | RUSH UNIVERSITY MEDICAL CENTER (US) | 2019-07-11 | — | — | WO | disclosed |
| US-20190151311-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190135784-A1 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| EP-3474900-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190119294-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190119243-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | G1 THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3454862-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-3455219-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-3454856-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-3455218-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20190055209-A1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-02-21 | — | — | US | disclosed |
| US-10208011-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20190022225-A1 | PROTOCOL FOR INCREASING LIFE EXPECTANCY IN A TEST SUBJECT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-01-24 | — | — | US | disclosed |
| US-20190016703-A1 | BIFUNCTIONAL COMPOUNDS FOR HER3 DEGRADATION AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-01-17 | — | — | US | disclosed |
| US-20180369230-A1 | TARGETED SELECTION OF PATIENTS FOR TREATMENT WITH SPECIFIC CORTISTATIN DERIVATIVES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-12-27 | — | — | US | disclosed |
| US-20180326078-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2018-11-15 | — | — | US | disclosed |
| US-10118910-B2 | Benzothiophene-based selective estrogen receptor downregulators | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-11-06 | — | — | US | disclosed |
| US-20180298024-A1 | CORTISTATIN ANALOGS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-10-18 | — | — | US | disclosed |
| WO-2018175340-A1 | REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018175302-A1 | POLYMER CONJUGATES TARGETING C-SRC WITH REDUCED EXPOSURE | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| EP-3083648-B1 | PHARMACEUTICAL PROCESS AND INTERMEDIATES | RIGEL PHARMACEUTICALS INC (US) | 2018-09-12 | — | — | EP | disclosed |
| US-10028975-B2 | Methods for treating ischemia-reperfusion injury | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180193458-A1 | COMPOSITIONS AND METHODS FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | BUCK INSTITUTE FOR RESEARCH ON AGING | 2018-07-12 | — | — | US | disclosed |
| US-20180153912-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153912-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180135134-A1 | TARGETED SELECTION OF PATIENTS FOR TREATMENT WITH CORTISTATIN DERIVATIVES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-05-17 | — | — | US | disclosed |
| EP-2217241-B1 | WET GRANULATION USING A WATER SEQUESTERING AGENT | RIGEL PHARMACEUTICALS INC (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-2217241-B1 | WET GRANULATION USING A WATER SEQUESTERING AGENT | RIGEL PHARMACEUTICALS INC (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2018058098-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE | YALE UNIVERSITY (US) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018053189-A2 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| US-20180078552-A1 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | PURDUE RESEARCH FOUNDATION | 2018-03-22 | — | — | US | disclosed |
| US-20180078552-A1 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | PURDUE RESEARCH FOUNDATION | 2018-03-22 | — | — | US | disclosed |
| US-20180015137-A1 | ANTI-SENESCENCE COMPOUNDS AND USES THEREOF | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2018-01-18 | — | — | US | disclosed |
| US-20180015137-A1 | ANTI-SENESCENCE COMPOUNDS AND USES THEREOF | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2018-01-18 | — | — | US | disclosed |
| WO-2017223452-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017197046-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017197036-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017197051-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017197056-A1 | BROMODOMAIN TARGETING DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017197055-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20170291909-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170291909-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-10-12 | — | — | US | disclosed |
| US-9737554-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9737554-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| US-9695204-B2 | Pharmaceutical process and intermediates | RIGEL PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695204-B2 | Pharmaceutical process and intermediates | RIGEL PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695204-B2 | Pharmaceutical process and intermediates | RIGEL PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170166551-A1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166550-A1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-06-15 | — | — | US | disclosed |
| US-9567641-B2 | Combination therapy for the treatment of cancer using an anti-C-met antibody | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-02-14 | — | — | US | disclosed |
| US-9532998-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160367575-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160367575-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160355531-A1 | Pharmaceutical Process and Intermediates | MIDCAP FINANCIAL TRUST | 2016-12-08 | — | — | US | disclosed |
| US-20160355531-A1 | Pharmaceutical Process and Intermediates | MIDCAP FINANCIAL TRUST | 2016-12-08 | — | — | US | disclosed |
| US-20160355531-A1 | Pharmaceutical Process and Intermediates | MIDCAP FINANCIAL TRUST | 2016-12-08 | — | — | US | disclosed |
| WO-2016172053-A1 | METHODS OF TREATING IBRUTINIB-RESISTANT DISEASE | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| EP-2252300-B1 | USE OF 2,4-PYRIMIDINEDIAMINES FOR THE TREATMENT OF ATHEROSCLEROSIS | RIGEL PHARMACEUTICALS INC (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20160220569-A1 | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy | G1 THERAPEUTICS, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160199402-A1 | METHODS FOR TREATING ISCHEMIA-REPERFUSION INJURY | BETH ISRAEL DEACONESS MEDICAL CENTER | 2016-07-14 | — | — | US | disclosed |
| US-9388203-B2 | Pharmaceutical process and intermediates | MIDCAP FINANCIAL TRUST | 2016-07-12 | — | — | US | disclosed |
| US-9388203-B2 | Pharmaceutical process and intermediates | MIDCAP FINANCIAL TRUST | 2016-07-12 | — | — | US | disclosed |
| US-9388203-B2 | Pharmaceutical process and intermediates | MIDCAP FINANCIAL TRUST | 2016-07-12 | — | — | US | disclosed |
| US-20160136191-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160136191-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-9283238-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9266912-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266912-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| EP-2448950-B1 | SYNTHESIS OF N4-(2,2-DIMETHYL-4-[(DIHYDROGEN PHOSPHONOXY)METHYL]-3-OXO-5-PYRIDO[1,4]OXAZIN-6-YL)-5-FLUORO-N2-(3,4,5-TRIMETHOXYPHENYL)-2,4-PYRIMIDINEDIAMINE DISODIUM SALT | RIGEL PHARMACEUTICALS INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20150366866-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | FOUNDATION MEDICINE, INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150366866-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | FOUNDATION MEDICINE, INC. | 2015-12-24 | — | — | US | disclosed |
| WO-2015095765-A1 | PHARMACEUTICAL PROCESS AND INTERMEDIATES | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175639-A1 | Pharmaceutical Process and Intermediates | MIDCAP FINANCIAL TRUST | 2015-06-25 | — | — | US | disclosed |
| US-20150175639-A1 | Pharmaceutical Process and Intermediates | MIDCAP FINANCIAL TRUST | 2015-06-25 | — | — | US | disclosed |
| US-20150175639-A1 | Pharmaceutical Process and Intermediates | MIDCAP FINANCIAL TRUST | 2015-06-25 | — | — | US | disclosed |
| US-20150133404-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-14 | — | — | US | disclosed |
| US-20150133404-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-14 | — | — | US | disclosed |
| US-8951504-B2 | (trimethoxyphenylamino) pyrimidinyl formulations | RIGEL PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8951504-B2 | (trimethoxyphenylamino) pyrimidinyl formulations | RIGEL PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150010575-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING AN ANTI-C-MET ANTIBODY | GEORGETOWN UNIVERSITY | 2015-01-08 | — | — | US | disclosed |
| US-8912170-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912170-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140357598-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140357598-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140309233-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | HULOW, LLC (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309233-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | HULOW, LLC (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140271493-A1 | (Trimethoxyphenylamino) Pyrimidinyl Formulations | RIGEL PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271493-A1 | (Trimethoxyphenylamino) Pyrimidinyl Formulations | RIGEL PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2501705-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8785437-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785437-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8771648-B2 | (Trimethoxyphenylamino) pyrimidinyl formulations | RIGEL PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8771648-B2 | (Trimethoxyphenylamino) pyrimidinyl formulations | RIGEL PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8691798-B2 | Synthesis of 2,4-pyrimidinediamines | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-08 | — | — | US | disclosed |
| US-8691798-B2 | Synthesis of 2,4-pyrimidinediamines | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-08 | — | — | US | disclosed |
| EP-1968598-B1 | PYRIMIDINE-2,4-DIAMINES AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2014-02-19 | — | — | EP | disclosed |
| US-8652492-B2 | Wet granulation using a water sequestering agent | RIGEL PHARMACEUTICAL, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8652492-B2 | Wet granulation using a water sequestering agent | RIGEL PHARMACEUTICAL, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8652492-B2 | Wet granulation using a water sequestering agent | RIGEL PHARMACEUTICAL, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8642593-B2 | 2,4-pyrimidinediamine compounds and prodrugs and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642593-B2 | 2,4-pyrimidinediamine compounds and prodrugs and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130310341-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | MIDCAP FINANCIAL TRUST | 2013-11-21 | — | — | US | disclosed |
| US-20130274499-A1 | Synthesis of 2,4-Pyrimidinediamines | MIDCAP FINANCIAL TRUST | 2013-10-17 | — | — | US | disclosed |
| US-20130274499-A1 | Synthesis of 2,4-Pyrimidinediamines | MIDCAP FINANCIAL TRUST | 2013-10-17 | — | — | US | disclosed |
| US-8530466-B2 | Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130189359-A1 | Wet Granulation Using a Water Sequestering Agent | RIGEL PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130189359-A1 | Wet Granulation Using a Water Sequestering Agent | RIGEL PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130189359-A1 | Wet Granulation Using a Water Sequestering Agent | RIGEL PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-8481521-B2 | Methods of treating cell proliferative disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481724-B2 | Synthesis of 2,4-pyrimidinediamines | RIGEL PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481724-B2 | Synthesis of 2,4-pyrimidinediamines | RIGEL PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481521-B2 | Methods of treating cell proliferative disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8476263-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476263-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130150329-A1 | 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8445485-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445485-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| EP-1656372-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR USE IN THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES | RIGEL PHARMACEUTICALS INC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20130058876-A1 | (TRIMETHOXYPHENYLAMINO) PYRIMIDINYL FORMULATIONS | ASTRAZENECA AB | 2013-03-07 | — | — | US | disclosed |
| US-20130058876-A1 | (TRIMETHOXYPHENYLAMINO) PYRIMIDINYL FORMULATIONS | ASTRAZENECA AB | 2013-03-07 | — | — | US | disclosed |
| US-8389515-B2 | 2,4-pyrimidinediamine compounds and prodrugs and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389515-B2 | 2,4-pyrimidinediamine compounds and prodrugs and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8372415-B2 | Wet granulation using a water sequestering agent | RIGEL PHARMACEUTICALS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372415-B2 | Wet granulation using a water sequestering agent | RIGEL PHARMACEUTICALS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372415-B2 | Wet granulation using a water sequestering agent | RIGEL PHARMACEUTICALS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| WO-2013014454-A1 | NEW (TRIMETHOXYPHENYLAMINO)PYRIMIDINYL FORMULATIONS | ASTRAZENECA AB (SE) | 2013-01-31 | — | — | WO | disclosed |
| US-20130018185-A1 | Synthesis of 2,4-Pyrimidinediamines | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018185-A1 | Synthesis of 2,4-Pyrimidinediamines | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| EP-2539347-A2 | TRIMETHOXYPHENYL INHIBITORS OF TYROSINE KINASE | Auspex Pharmaceuticals, Inc. (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120288543-A1 | Wet Granulation Using A Water Sequestering Agent | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120288543-A1 | Wet Granulation Using A Water Sequestering Agent | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120288543-A1 | Wet Granulation Using A Water Sequestering Agent | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-8299242-B2 | Synthesis of 2,4-pyrimidinediamines | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120245127-A1 | Methods of Treating Cell Proliferative Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245127-A1 | Methods of Treating Cell Proliferative Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120232036-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232036-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-8263122-B2 | Wet granulation using a water sequestering agent | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263122-B2 | Wet granulation using a water sequestering agent | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263122-B2 | Wet granulation using a water sequestering agent | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120208785-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208785-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8227455-B2 | Methods of treating cell proliferative disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227455-B2 | Methods of treating cell proliferative disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8211888-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211889-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211888-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211889-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120108810-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108810-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8163902-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163902-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110319613-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319613-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011106248-A2 | TRIMETHOXYPHENYL INHIBITORS OF TYROSINE KINASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20110206661-A1 | TRIMETHOXYPHENYL INHIBITORS OF TYROSINE KINASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110206661-A1 | TRIMETHOXYPHENYL INHIBITORS OF TYROSINE KINASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-7989448-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989448-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110144059-A1 | PRODRUGS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20110144059-A1 | PRODRUGS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20110124599-A1 | 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124599-A1 | 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110046126-A1 | Use of 2,4-Pyrimidinediamines For the Treatment of Atherosclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2010181-B1 | METHODS OF TREATING CELL PROLIFERATIVE DISORDERS BY USING PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS INC (US) | 2011-02-23 | — | — | EP | disclosed |
| WO-2011009075-A2 | DEUTERATED 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015155-A1 | Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015155-A1 | Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| WO-2011002999-A1 | SYNTHESIS OF N4- (2, 2-DIMETHYL-4- [ (DIHYDROGEN PHOSPHONOXY ] -3-OXO-5-PYRIDO [1, 4] OXAZIN-6-YL)-5-FLUORO-N2- (3, 4, 5,-TRIMETHOXYPHENYL) -2, 4- PYRIMIDINEDIAMINE DISODIUM SALT | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20110003986-A1 | Synthesis of 2,4-Pyrimidinediamines | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003986-A1 | Synthesis of 2,4-Pyrimidinediamines | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| EP-2252300-A1 | USE OF 2,4-PYRIMIDINEDIAMINES FOR THE TREATMENT OF ATHEROSCLEROSIS | Rigel Pharmaceuticals, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7713987-B2 | Pyrimidine-2,4-diamines and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713987-B2 | Pyrimidine-2,4-diamines and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-2161275-A1 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmaceuticals, Inc. (US) | 2010-03-10 | — | — | EP | disclosed |
| WO-2009105675-A1 | USE OF 2,4-PYRIMIDINEDIAMINES FOR THE TREATMENT OF ATHEROSCLEROSIS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
| US-7563892-B1 | Prodrugs of 2,4 pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563892-B1 | Prodrugs of 2,4 pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7538108-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538108-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20090124580-A1 | Autoimmune diseases; water solubility of prodrug can be tailored to improve bioavailability using substution at amine groups; inhibitors of degranulation of immune cells; inhibit/activate Fc receptor signaling cascades | RIGEL PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090124580-A1 | Autoimmune diseases; water solubility of prodrug can be tailored to improve bioavailability using substution at amine groups; inhibitors of degranulation of immune cells; inhibit/activate Fc receptor signaling cascades | RIGEL PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090123539-A1 | WET GRANULATION USING A WATER SEQUESTERING AGENT | RIGEL PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090123539-A1 | WET GRANULATION USING A WATER SEQUESTERING AGENT | RIGEL PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090123539-A1 | WET GRANULATION USING A WATER SEQUESTERING AGENT | RIGEL PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090048214-A1 | Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds | RIGEL PHARMACEUTICALS, INC (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048214-A1 | Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds | RIGEL PHARMACEUTICALS, INC (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090012045-A1 | Methods of Treating Cell Proliferative Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012045-A1 | Methods of Treating Cell Proliferative Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012045-A1 | Methods of Treating Cell Proliferative Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2009003136-A1 | SUBSTITUTED PYRIMIDINE-2, 4 -DIAMINES FOR TREATING CELL PROLIFERATIVE DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-7449458-B2 | Autoimmune diseases; water solubility of prodrug can be tailored to improve bioavailability using substution at amine groups; inhibitors of degranulation of immune cells; inhibit/activate Fc receptor signaling cascades; tyrosine kinase Syk kinase inhibitor; collagen-induced platelet activation inhibitor | RIGEL PHARMACEUTICALS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449458-B2 | Autoimmune diseases; water solubility of prodrug can be tailored to improve bioavailability using substution at amine groups; inhibitors of degranulation of immune cells; inhibit/activate Fc receptor signaling cascades; tyrosine kinase Syk kinase inhibitor; collagen-induced platelet activation inhibitor | RIGEL PHARMACEUTICALS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| WO-2007124221-A1 | METHODS OF TREATING CELL PROLIFERATIVE DISORDERS BY USING PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070129362-A1 | Pyrimidine-2,4-diamines and their uses | MIDCAP FINANCIAL TRUST | 2007-06-07 | — | — | US | disclosed |
| US-20070129362-A1 | Pyrimidine-2,4-diamines and their uses | MIDCAP FINANCIAL TRUST | 2007-06-07 | — | — | US | disclosed |
| US-20070129362-A1 | Pyrimidine-2,4-diamines and their uses | MIDCAP FINANCIAL TRUST | 2007-06-07 | — | — | US | disclosed |
| US-20070129360-A1 | N2-Chlorocarbonyl-N4-(2,2-dimethyl-3-oxo-4H-5-pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine; kinase inhibitors; breast cancer; inhibiting signal transduction cascades in which Syk plays a role | PHAMIDIPATI SOMASEKHAR | 2007-06-07 | — | — | US | disclosed |
| US-20070129360-A1 | N2-Chlorocarbonyl-N4-(2,2-dimethyl-3-oxo-4H-5-pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine; kinase inhibitors; breast cancer; inhibiting signal transduction cascades in which Syk plays a role | PHAMIDIPATI SOMASEKHAR | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355531-A1 | Pharmaceutical Process and Intermediates | CYP3A4, UGT1A10, CYP3A5 | SYK 2361/4885PTK2 4080/4885AURKA 1479/4885 |
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | SYK 2578/4885PTK2 2236/4885AURKA 1283/4885 |
| US-20240287061-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | SYK 3662/4885PTK2 569/4885AURKA 582/4885 |
| US-11723947-B2 | Anti-senescence compounds and uses thereof | LIMS1, GLA, AGER | SYK 4732/4885PTK2 2325/4885AURKA 3791/4885 |
| US-20130018185-A1 | Synthesis of 2,4-Pyrimidinediamines | DPYD, TYMS, TYMP | SYK 3076/4885PTK2 3591/4885AURKA 484/4885 |
| US-20180078552-A1 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | SYK, BTK, CD47 | SYK 1/4885PTK2 80/4885AURKA 1226/4885 |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | SYK 4006/4885PTK2 1173/4885AURKA 853/4885 |
| US-20220175689-A1 | NOVEL DRUG DELIVERY COMPOSITION AND PROCESS FOR BLOOD-BRAIN BARRIER CROSSING | FABP7, TIE1, LDLR | SYK 2208/4885PTK2 656/4885AURKA 2096/4885 |
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | SYK 4299/4885PTK2 4434/4885AURKA 2098/4885 |
| US-20220073473-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | SYK 634/4885PTK2 1348/4885AURKA 4643/4885 |
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | SYK 2314/4885PTK2 3011/4885AURKA 4081/4885 |
| US-12258346-B2 | Substituted 6-azabenzimidazole compounds | CDK6, HIPK1, DCK | SYK 3662/4885PTK2 569/4885AURKA 582/4885 |
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | WRN, RECQL, BLM | SYK 4483/4885PTK2 3133/4885AURKA 2289/4885 |
| US-20220226336-A1 | COMBINATION THERAPY FOR TREATING CANCER | EZH2, BMI1, HDAC2 | SYK 1447/4885PTK2 516/4885AURKA 1078/4885 |
| US-20110206661-A1 | TRIMETHOXYPHENYL INHIBITORS OF TYROSINE KINASE | ABL1, LCK, SRC | SYK 30/4885PTK2 54/4885AURKA 399/4885 |
| US-20130310341-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | DPYD, TYMP, DCTD | SYK 2198/4885PTK2 4081/4885AURKA 678/4885 |
| US-20200405721-A1 | G1T38 SUPERIOR DOSAGE REGIMES | CXCL8, ELANE, CD4 | SYK 1487/4885PTK2 4653/4885AURKA 3508/4885 |
| US-20220000880-A1 | METHOD AND COMPOSITION EMBODIMENTS FOR TREATING ACUTE MYELOID LEUKEMIA | MCL1, FLT3, ABL1 | SYK 446/4885PTK2 2258/4885AURKA 242/4885 |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | SYK 4077/4885PTK2 3186/4885AURKA 1192/4885 |
| US-20240245677-A1 | SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRIX1, BRWD1 | SYK 4729/4885PTK2 2579/4885AURKA 2755/4885 |
| US-12358887-B2 | IKAROS Zinc Finger Family degraders and uses thereof | IKZF2, IKZF1, IKZF3 | SYK 1415/4885PTK2 4132/4885AURKA 930/4885 |
| US-20140357598-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | DPYD, TYMP, DCTD | SYK 2055/4885PTK2 3230/4885AURKA 617/4885 |
| US-20190247509-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BRD9, BRWD1, BRD1 | SYK 4172/4885PTK2 3989/4885AURKA 2870/4885 |
| US-20240199581-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | BRAF, NRAS, KRAS | SYK 2053/4885PTK2 2511/4885AURKA 635/4885 |
| US-12285431-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | RB1, CDK4, CDK6 | SYK 2925/4885PTK2 2033/4885AURKA 127/4885 |
| US-20180298024-A1 | CORTISTATIN ANALOGS AND USES THEREOF | CTTN, CLSPN, KCNN2 | SYK 3045/4885PTK2 1373/4885AURKA 1695/4885 |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | SYK 4313/4885PTK2 3464/4885AURKA 4090/4885 |
| US-12441740-B2 | N/O-linked degrons and degronimers for protein degradation | CRBN, CBL, STUB1 | SYK 1357/4885PTK2 3913/4885AURKA 2540/4885 |
| US-20230128322-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | SYK, BTK, MERTK | SYK 1/4885PTK2 42/4885AURKA 168/4885 |
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | SYK 4557/4885PTK2 2948/4885AURKA 2306/4885 |
| US-12269812-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | SYK 3277/4885PTK2 1931/4885AURKA 568/4885 |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | SYK 4263/4885PTK2 3210/4885AURKA 337/4885 |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | SYK 4516/4885PTK2 3763/4885AURKA 2956/4885 |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | SYK 1945/4885PTK2 407/4885AURKA 995/4885 |
| US-20190292197-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | DPYD, TYMP, DCTD | SYK 2055/4885PTK2 3230/4885AURKA 617/4885 |
| US-20230312736-A1 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | CCR8, CCR4, CCR3 | SYK 3592/4885PTK2 2501/4885AURKA 1855/4885 |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | SYK 4436/4885PTK2 912/4885AURKA 2002/4885 |
| US-11795223-B2 | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia | CD47, MCL1, MYADM | SYK 836/4885PTK2 2202/4885AURKA 1540/4885 |
| US-20180015137-A1 | ANTI-SENESCENCE COMPOUNDS AND USES THEREOF | LIMS1, GLA, AGER | SYK 4770/4885PTK2 2374/4885AURKA 3937/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | SYK 3294/4885PTK2 1412/4885AURKA 576/4885 |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | SYK 3875/4885PTK2 3852/4885AURKA 2047/4885 |
| US-11555029-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | SYK 3814/4885PTK2 2392/4885AURKA 932/4885 |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | PSMC3, PSMA6, ADRM1 | SYK 3114/4885PTK2 3333/4885AURKA 3332/4885 |
| US-20230060004-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | SYK 1871/4885PTK2 232/4885AURKA 1040/4885 |
| US-11925631-B2 | Substituted 6-azabenzimidazole compounds | CDK6, HIPK1, DCK | SYK 3662/4885PTK2 569/4885AURKA 582/4885 |
| US-20250101037-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBL, STUB1 | SYK 1357/4885PTK2 3913/4885AURKA 2540/4885 |
| US-20200123168-A1 | MORPHIC FORMS OF G1T38 AND METHODS OF MANUFACTURE THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB8A, UGT1A8 | SYK 3901/4885PTK2 4700/4885AURKA 4594/4885 |
| US-20250270226-A1 | SUBSTITUTED 1',2'-DIHYDRO-3'H-SPIRO[CYCLOHEXANE-1,4'-PYRIMIDO[5',4':4,5]PYRROLO[2,1-c][1,2,4]TRIAZIN]-3'-ONES AS CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CCNI, CCNK | SYK 1969/4885PTK2 259/4885AURKA 120/4885 |
| US-11951109-B2 | EZH2 inhibitors for treating lymphoma | EZH2, BMI1, BCL6 | SYK 1201/4885PTK2 726/4885AURKA 1503/4885 |
| US-10807964-B2 | Benzothiophene-based selective estrogen receptor downregulators | ESR1, ESR2, GPER1 | SYK 3853/4885PTK2 3702/4885AURKA 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.